A Phase 1 Randomized, Placebo-Controlled Study of LY3316531 in Healthy Subjects and an Open-Label, Single-Dose Study in Patients With Psoriasis
Phase of Trial: Phase I
Latest Information Update: 07 Jan 2019
At a glance
- Drugs LY-3316531 (Primary) ; LY-3316531 (Primary)
- Indications Plaque psoriasis
- Focus Adverse reactions
- Sponsors Eli Lilly
- 12 Sep 2018 Planned End Date changed from 1 Sep 2019 to 2 Sep 2019.
- 12 Sep 2018 Planned primary completion date changed from 1 Feb 2019 to 12 Feb 2019.
- 06 Feb 2018 New trial record